Lumicell Diagnostics Inc. hit the $1 million goal for its funding round.
Wellesley, Mass.-based Lumicell is developing a hand-held imaging system designed to give physicians a better picture of the amount of cancer remaining at tumor sites during surgery – oncology surgery’s holy grail of “clean margins.”
The medtech company’s intraoperative imaging system includes a cancer-targeted injectable imaging agent, according to Lumicell’s website. The system is designed to deliver real-time imaging and single-cell detection in a wide field of view during procedures.
"Real-time cancer detection, unique to this surgical system, will enable the surgeon to provide clean margins, eliminating the need for a second operation. This also decreases or eliminates the risk of local cancer recurrence. Lumicell’s surgical system will reduce the patient’s need for adjuvant therapy such as radiation and chemotherapy. Lumicell is initially investigating its imaging system in patients undergoing surgery for breast cancer and sarcomas. The Lumicell team is focused on five additional cancer indications in the near term," according to the website.
The Series B equity and preferred stock offering brought in 5 backers, according to a regulatory filing.
